In this context, inhibitors of the colony-stimulating factor 1 (CSF1) receptor (CSF1R) have emerged as promising drug candidates against AD neuroinflammation (Sosna et al., 2018; Hu et al., 2021). Here, CSF1R is linked to Alzheimer disease.